Free 7-day Trial
All Articles and Columns »

10 Best Dividend Paying Drug Manufacturing Stocks

The best dividend paying stocks from the major drug manufacturing industry originally published at "long-term-investments.blogspot.com". The healthcare sector is another great investment field for me. I mainly like it because of the ongoing aging population. The older people are, the more healthcare they need. The big problem is that most of the people have not saved enough money to finance all their health services and products. The government must provide care via health care plans, insurance, hospitals, education, and so on. This also means a state related dependence for the investor.

One of the best yielding industries within the healthcare sector is the major drug manufacturing industry. The average yield amounts to 3.85% and the P/Es on a level of 18.0. The industry has exactly ten dividend stocks and is still the biggest investment field followed by a ten times smaller biotechnology industry. I believe that the biotechs will perform better and catch up to the leading industry if the old drug companies do not overtake them. The reason is simple: Biotechs are more innovative.

However, below are a few of the best dividend paying major drug manufacturing stocks. Out of ten stocks on the list, there are seven with a buy or even better rating. Despite the great predictions of decreasing sales and earnings due to patent losses, growth is still forecasted for the most of the drug dividend stocks.

Here are my favorite stocks:

GlaxoSmithKline (GSK) has a market capitalization of $108.42 billion. The company employs 97,389 people, generates revenue of $39.741 billion and has a net income of $7.133 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $11.831 billion. The EBITDA margin is 29.77% (the operating margin is 27.97% and the net profit margin 17.95%).

Financial Analysis: The total debt represents 44.13% of the company’s assets and the total debt in relation to the equity amounts to 315.01%. Due to the financial situation, a return on equity of 65.96% was realized. Twelve trailing months earnings per share reached a value of $2.73. Last fiscal year, the company paid $2.23 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 16.22, the P/S ratio is 2.74 and the P/B ratio is finally 12.41. The dividend yield amounts to 5.30% and the beta ratio has a value of 0.63.

Sanofi (SNY) has a market capitalization of $124.12 billion. The company employs 113,719 people, generates revenue of $45.771 billion and has a net income of $6.350 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $13.360 billion. The EBITDA margin is 29.19% (the operating margin is 16.18% and the net profit margin 13.87%).

Financial Analysis: The total debt represents 15.41% of the company’s assets and the total debt in relation to the equity amounts to 27.46%. Due to the financial situation, a return on equity of 10.42% was realized. Twelve trailing months earnings per share reached a value of $2.95. Last fiscal year, the company paid $1.73 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 15.94, the P/S ratio is 2.76 and the P/B ratio is finally 1.70. The dividend yield amounts to 3.94 percent and the beta ratio has a value of 0.90.

Bristol Myers Squibb (BMY) has a market capitalization of $60.83 billion. The company employs 28,000 people, generates revenue of $17.621 billion and has a net income of $2.501 billion. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $3.222 billion. The EBITDA margin is 18.28% (the operating margin is 13.28% and the net profit margin 14.19%).

Financial Analysis: The total debt represents 20.60% of the company’s assets and the total debt in relation to the equity amounts to 54.28%. Due to the financial situation, a return on equity of 13.25% was realized. Twelve trailing months earnings per share reached a value of $1.15. Last fiscal year, the company paid $1.37 in the form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 32.22, the P/S ratio is 3.45 and the P/B ratio is finally 4.45. The dividend yield amounts to 3.77% and the beta ratio has a value of 0.42.

Take a closer look at the full list of the best dividend paying drug stocks. The average P/E ratio amounts to 18.66 and forward P/E ratio is 13.35. The dividend yield has a value of 4.27%. Price to book ratio is 4.21 and price to sales ratio 2.84. The operating margin amounts to 20.82% and the beta ratio is 0.65. Stocks from the list have an average debt to equity ratio of 2.56.

Related stock ticker symbols:

AZN, GSK, ABBV, MRK, BMY, NVS, SNY, LLY, PFE, JNJ, ETE

Selected Articles:

· 20 Of The Best Yielding Healthcare Growth Stocks For The Next Years

· Most Recommended Healthcare Stocks For 2013

· My Best Healthcare Stock Picks For 2013

· 20 Of The Biggest Healthcare Dividend Payer

If you like to receive more news and regular dividend updates, you should subscribe to my free E-Mail list. Alternative, you can follow me onFacebookor Twitter.

About the author:

Dividend
I am a private full time investor searching for investments and investment ideas.

Visit Dividend's Website


Rating: 2.5/5 (4 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide